Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 269-274

  Steyerberg, E W ^a   Gerl, A ^a   Fossa S D ^a   Sleijfer, D T ^a   De Wit, R ^a   Kirkels, W J ^a   Schmeller, N ^a   Clemm, C ^a   Habbema, J D F ^a   Keizer, H J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; RETROPERITONEAL TUMOR; STATISTICAL ANALYSIS; STATISTICAL MODEL; TERATOMA; TESTIS CANCER; TUMOR NECROSIS;

EID: 0031961892     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.269     Document Type: Article

References (30)

1. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
2. Mead GM, Stenning SP, Parkinson MC, et al: The second medical research council study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 10:85-94, 1992
3. de Wit R, Stoter G, Sleijfer DT, et al: Four cycles of BEP versus alternating regime of PVB and BEP in patients with poor prognosis metastatic testicular non-seminoma: A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71:1311-1314, 1995
4. Gerl A, Clemm C, Schmeller N, et al: Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: A single-institution experience. Br J Cancer 74:1280-1285, 1996
5. Donohue JP, Birhle R, Foster RS: Evolving concepts in surgical management of testis cancer. Cancer Treat Res 59:89-97, 1992
6. Fox EP, Weathers TD, Williams SD, et al: Outcome analysis of patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11:1294-1299, 1993
7. Steyerberg EW, Keizer HJ, Fosså SD, et al: Prediction of residual retroperitoneal mass histology following chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from 6 study groups. J Clin Oncol 13:1177-1187, 1995
8. Harrell F, Lee K, Mark D: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
9. Gerl A, Clemm C, Schmeller N, et al: Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 6:483-488, 1995
10. Gelderman WAH, Schraffordt Koops H, Sleijfer DTh, et al: Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy. J Surg Oncol 38:227-232, 1988
11. Fosså SD, Qvist H, Stenwig AE, et al: Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 10:569-573, 1992
12. Steyerberg EW, Keizer HJ, Zwartendijk J, et al: Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: A multivariate analysis. Br J Cancer 68:195-200, 1993
13. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989
14. Harrell FE, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests. JAMA 247:2543-2546, 1982
15. Steyerberg EW, Keizer HJ, Stoter G, et al: Predictors of residual mass histology following chemotherapy for metastatic nonseminomatous testicular cancer: A quantitative overview of 996 resections. Eur J Cancer 30A:1231-1239, 1994
16. Efron B: Estimating the error rate of a prediction rule: Improvement on cross-validation. J Am Stat Assoc 78:316-331, 1983
17. Stephens AW, Gonin R, Hutchins GD, et al: Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14:1637-1641, 1996
18. Steyerberg EW, Keizer HJ, Fosså SD, et al: Resection of residual retroperitoneal masses in testicular cancer: Evaluation and improvement of selection criteria. Br J Cancer 74:1492-1498, 1996
19. Toner GC, Panicek DM, Heelan RT, et al: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 8:1683-1694, 1990
20. Donohue JP, Rowland RG, Kopecky K, et al: Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137:1176-1179, 1987
21. Debono DJ, Heilman DK, Einhorn LH, et al: Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455-1464, 1997
22. Baniel J, Foster RS, Gonin R, et al: Late relapse of testicular cancer. J Clin Oncol 13:1170-1176, 1995
23. Gerl A, Clemm C, Schmeller N, et al: Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8:41-47, 1997
24. Aprikian AG, Herr HW, Bajorin DF, et al: Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 74:1329-1334, 1994
25. Levi JA, Raghavan D, Harvey V, et al: The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol 11:1300-1305, 1993
26. Loehrer PJ, Johnson D, Elson P, et al: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470-476, 1995
27. de Wit R, Stoter G, Kaye S, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15:1837-1843, 1997
28. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1453-1440, 1987
29. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11:598-606, 1993
30. Horwich A. Sleijfer DT, Fosså SD, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15:1844-1852, 1997